Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2
- PMID: 31611221
- DOI: 10.1136/annrheumdis-2019-216246
Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2
Keywords: dermatomyositis; polymyositis; treatment.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Circulating regulatory T cells were absolutelydecreased in dermatomyositis/polymyositispatients and restored by low-dose IL-2' by Zhang et al.Ann Rheum Dis. 2021 Aug;80(8):e131. doi: 10.1136/annrheumdis-2019-216267. Epub 2019 Oct 14. Ann Rheum Dis. 2021. PMID: 31611217 No abstract available.
Comment on
-
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.Ann Rheum Dis. 2019 Feb;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229. Epub 2018 Nov 24. Ann Rheum Dis. 2019. PMID: 30472651 Clinical Trial.
Similar articles
-
Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis.Ann Rheum Dis. 2012 Jun;71(6):1055-63. doi: 10.1136/annrheumdis-2011-200495. Epub 2012 Jan 20. Ann Rheum Dis. 2012. PMID: 22267334 Clinical Trial.
-
Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis.Int Immunopharmacol. 2019 Dec;77:105912. doi: 10.1016/j.intimp.2019.105912. Epub 2019 Oct 24. Int Immunopharmacol. 2019. PMID: 31669890 Clinical Trial.
-
Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis.Arthritis Rheum. 2000 Feb;43(2):336-48. doi: 10.1002/1529-0131(200002)43:2<336::AID-ANR13>3.0.CO;2-V. Arthritis Rheum. 2000. PMID: 10693873
-
Biologics in polymyositis and dermatomyositis-associated interstitial lung disease.Curr Pharm Biotechnol. 2014;15(6):521-4. doi: 10.2174/138920101506140910145940. Curr Pharm Biotechnol. 2014. PMID: 25213360 Review.
-
Immunomodulatory treatment for dermatomyositis.Curr Allergy Asthma Rep. 2008 Jul;8(4):348-53. doi: 10.1007/s11882-008-0055-1. Curr Allergy Asthma Rep. 2008. PMID: 18606089 Review.
Cited by
-
Imbalance of peripheral blood Th17/Treg increases neutrophil-to-lymphocyte ratio in patients with dermatomyositis.Am J Transl Res. 2023 Oct 15;15(10):6106-6114. eCollection 2023. Am J Transl Res. 2023. PMID: 37969179 Free PMC article.
-
NLRP3 inflammasome up-regulates major histocompatibility complex class I expression and promotes inflammatory infiltration in polymyositis.BMC Immunol. 2022 Aug 14;23(1):39. doi: 10.1186/s12865-022-00515-2. BMC Immunol. 2022. PMID: 35965334 Free PMC article.
-
A comprehensive review of dermatomyositis treatments - from rediscovered classics to promising horizons.Expert Rev Clin Immunol. 2024 Feb;20(2):197-209. doi: 10.1080/1744666X.2023.2270737. Epub 2024 Jan 21. Expert Rev Clin Immunol. 2024. PMID: 37842905 Free PMC article. Review.
-
Coexistent Relapsing Polychondritis and Clinically Amyopathic Dermatomyositis: A Rare Association of Autoimmune Disorders.Case Rep Rheumatol. 2023 Apr 11;2023:3719502. doi: 10.1155/2023/3719502. eCollection 2023. Case Rep Rheumatol. 2023. PMID: 37082027 Free PMC article.
-
Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis.Ther Adv Musculoskelet Dis. 2021 Apr 28;13:1759720X211011370. doi: 10.1177/1759720X211011370. eCollection 2021. Ther Adv Musculoskelet Dis. 2021. PMID: 33995604 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources